Title | SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. |
Publication Type | Journal Article |
Year of Publication | 2013 |
Authors | Ramezani-Rad, Parham, Geng Huimin, Hurtz Christian, Chan Lai N., Chen Zhengshan, Jumaa Hassan, Melnick Ari, Paietta Elisabeth, Carroll William L., Willman Cheryl L., Lefebvre Véronique, and Müschen Markus |
Journal | Blood |
Volume | 121 |
Issue | 1 |
Pagination | 148-55 |
Date Published | 2013 Jan 03 |
ISSN | 1528-0020 |
Keywords | Animals, B-Lymphocytes, Benzamides, Cell Survival, Child, DNA Methylation, Gene Expression Regulation, Leukemic, Humans, Imatinib Mesylate, Kaplan-Meier Estimate, Mice, Mice, Inbred NOD, Mice, SCID, Multicenter Studies as Topic, Neoplasm Proteins, Piperazines, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Promoter Regions, Genetic, Proportional Hazards Models, Protein Kinase Inhibitors, Pyrimidines, Radiation Chimera, Randomized Controlled Trials as Topic, Signal Transduction, SOXC Transcription Factors, Tumor Cells, Cultured, Tumor Stem Cell Assay |
Abstract | <p>The Sox4 transcription factor mediates early B-cell differentiation. Compared with normal pre-B cells, SOX4 promoter regions in Ph(+) ALL cells are significantly hypomethylated. Loss and gain-of-function experiments identified Sox4 as a critical activator of PI3K/AKT and MAPK signaling in ALL cells. ChIP experiments confirmed that SOX4 binds to and transcriptionally activates promoters of multiple components within the PI3K/AKT and MAPK signaling pathways. Cre-mediated deletion of Sox4 had little effect on normal pre-B cells but compromised proliferation and viability of leukemia cells, which was rescued by BCL2L1 and constitutively active AKT and p110 PI3K. Consistent with these findings, high levels of SOX4 expression in ALL cells at the time of diagnosis predicted poor outcome in a pediatric clinical trial (COG P9906). Collectively, these studies identify SOX4 as a central mediator of oncogenic PI3K/AKT and MAPK signaling in ALL.</p> |
DOI | 10.1182/blood-2012-05-428938 |
Alternate Journal | Blood |
PubMed ID | 23152540 |
PubMed Central ID | PMC3538327 |
Grant List | R01 AR054153 / AR / NIAMS NIH HHS / United States R01AR54153 / AR / NIAMS NIH HHS / United States R21 CA152497 / CA / NCI NIH HHS / United States R21CA152497 / CA / NCI NIH HHS / United States R01 CA157644 / CA / NCI NIH HHS / United States R01 CA172558 / CA / NCI NIH HHS / United States U01 CA157937 / CA / NCI NIH HHS / United States R01CA169458 / CA / NCI NIH HHS / United States U24 CA114737 / CA / NCI NIH HHS / United States R01CA139032 / CA / NCI NIH HHS / United States R01 CA137060 / CA / NCI NIH HHS / United States R01CA137060 / CA / NCI NIH HHS / United States R01 CA169458 / CA / NCI NIH HHS / United States R01 CA139032 / CA / NCI NIH HHS / United States R01CA157644 / CA / NCI NIH HHS / United States |